Daphné Morel

TL;DR: The mechanisms by which epi-drugs can modulate the sensitivity of cancer cells to other forms of anticancer therapy, including chemotherapy, radiation therapy, hormone therapy, molecularly targeted therapy and immunotherapy are described and clinical trial designs and drug development strategies aimed at optimizing the development of such combinations are outlined.

TL;DR: It is shown that ERCC1-defective non–small cell lung cancer (NSCLC) cells exhibit an enhanced type I IFN transcriptomic signature and that low ER CC1 expression correlates with increased lymphocytic infiltration and the data provide a preclinical rationale for using PARPi as immunomodulatory agents in appropriately molecularly selected populations.

TL;DR: In this paper, a series of orthogonal functional genomic screens were used to identify PARP and ATR inhibitors as being synthetic lethal with polybromo 1 deficiency in clear cell renal cell carcinomas (ccRCC).

TL;DR: This review provides an overview of the major principles of single-cell and conventional (bulk) RNA-seq applied to onco-immunology and gives examples of machine and deep learning models used to predict patient outcomes and treatment effect from high-dimensional data.

TL;DR: The latest breakthroughs and discoveries that inform the understanding of the m SWI/SNF complexes biology in carcinogenesis are reviewed, and the most promising therapeutic strategies to target mSWI/ SNF defects in human solid malignancies are discussed.